The estimated Net Worth of Kathryn E Stein is at least $346 millier dollars as of 7 January 2016. Kathryn Stein owns over 52,350 units of Macrogenics Inc stock worth over $345,909 and over the last 11 years Kathryn sold MGNX stock worth over $0.
Kathryn has made over 6 trades of the Macrogenics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Kathryn exercised 52,350 units of MGNX stock worth $45,021 on 7 January 2016.
The largest trade Kathryn's ever made was exercising 52,350 units of Macrogenics Inc stock on 7 January 2016 worth over $45,021. On average, Kathryn trades about 15,179 units every 74 days since 2013. As of 7 January 2016 Kathryn still owns at least 95,555 units of Macrogenics Inc stock.
You can see the complete history of Kathryn Stein stock trades at the bottom of the page.
Kathryn's mailing address filed with the SEC is C/O MACROGENICS, INC., 9640 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850.
Over the last 11 years, insiders at Macrogenics Inc have traded over $27,036,278 worth of Macrogenics Inc stock and bought 4,026,274 units worth $39,875,062 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Target N Vbb Biotech Ag Bio... et Edward Hurwitz. On average, Macrogenics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $132,068. The most recent stock trade was executed by Jay Philip Siegel on 20 May 2024, trading 4,500 units of MGNX stock currently worth $16,290.
a career at macrogenics could be waiting for you! please click on "careers" ---------------------------->>> to learn more. macrogenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. macrogenics creates both differentiated molecules that are directed to novel cancer targets, as well as “bio-betters,” which are drugs designed to improve upon marketed medicines. the combination of macrogenics’ technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. these are exciting times at macrogenics and we hope that you will take the opportunity to learn more about our organization, our pipeline and to view our job opportunities!
Macrogenics Inc executives and other stock owners filed with the SEC include: